Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN®)

Journal of Ophthalmic Inflammation and Infection

Table 1 Key benefits and safety monitoring associated with the 0.2 μg/day FAc implant

Key Benefits	Safety Monitoring
• Sustained control of ocular inflammation for up to 36 months which, compared with a sham injection, offers :[4] • Fewer uveitis recurrences • Longer periods before recurrence • Less potential for cumulative damage from repeated cycles of inflammation • Greater improvement in visual acuity • Reduced need for adjunctive treatments • The potential to minimise systemic adverse events* [3] (plasma levels of fluocinolone acetonide are below the lower limit of quantitation [1])	• Raised intraocular pressure • Cataract development

Notes: *Intravitreal delivery of corticosteroids offers a potentially improved safety profile relative to oral delivery (by minimising the potential for systemic adverse events), although showing this statistically [3] requires further study in a larger number of patients. Long-lasting therapy additionally helps to minimise the number of flares